HC Wainwright & Co. Initiates Coverage On Aktis Oncology with Buy Rating, Announces Price Target of $30
Benzinga Newsdesk 8 months ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Robert Burns initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Buy rating and announces Price Target of $30.
HC Wainwright & Co. analyst Robert Burns initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Buy rating and announces Price Target of $30.